

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0002028667
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer NovaBridge Biosciences
SEC File Number 001-39173
Address of Issuer SUITE 400, 2440 RESEARCH BLVD
ROCKVILLE
MARYLAND
20850
Phone (301) 670 2800
Name of Person for Whose Account the Securities are To Be Sold Skelton Joseph W.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer
Relationship to Issuer FORMER CFO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON STOCK	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	120000	519600.00	115270000	01/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of Person	Is	Date	Amount of	Date of	Nature of
--------------	----------	-----------	----------------	----	------	-----------	---------	-----------

Class	Acquired	Acquisition Transaction	from Whom Acquired	this a Gift?	Donor Acquired	Securities Acquired	Payment	Payment *
COMMON STOCK	01/02/2026	STOCK OPTION EXERCISE AND SALE PURSUANT TO 10B51 PLAN	NOVABRIDGE BIOSCIENCES	<input type="checkbox"/>		120000	01/02/2026	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks STOCK OPTION EXERCISE AND SALE PURSUANT TO A 10B51 PLAN THAT RUNS THRU CALENDAR YEAR 2026. THE PLAN WAS ESTABLISHED IN 2025

Date of Notice 01/02/2026

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 09/12/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature CONFORMED SIGNATURE ON FILE

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)